"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance

Stock Information for Evolus Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evolus Inc.

Evolus to Report First Quarter Financial Results on May 7, 2024
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
Evolus Announces Results from European Head-to-Head Filler Trial

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.